ArticleExperimental & molecular medicine2020
Zeb1 for RCP-induced oral cancer cell invasion and its suppression by resveratrol.
Article in Experimental & molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- The Role of Chemopreventive Agents in the Management of Oral Potentially Malignant Disorders and Oral Cancer: A Narrative Review.Cancer reports (Hoboken, N.J.) · 2026Review
- Acid stress modulates metabolo-inflammatory pathways in oral epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- Review
- Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities.Oncology research · 2026Review
- Roles of Selected Bioactive Compounds in Inhibiting the Development and Progression of Cancer-A Review.International journal of molecular sciences · 2025Review
- Resveratrol in the Treatment of Gynecological Cancer: Mechanisms and Therapeutic Potential.Current medicinal chemistry · 2025Review
- Rab25 suppresses colon cancer cell invasion through upregulating claudin‑7 expression.Oncology reports · 2024Article
- Chemopreventive and Biological Strategies in the Management of Oral Potentially Malignant and Malignant Disorders.Bioengineering (Basel, Switzerland) · 2024Review
- Chemopreventive and Anticancer Role of Resveratrol against Oral Squamous Cell Carcinoma.Pharmaceutics · 2023Review
- lncRNA CYTOR promotes aberrant glycolysis and mitochondrial respiration via HNRNPC-mediated ZEB1 stabilization in oral squamous cell carcinoma.Cell death & disease · 2022Article
- The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview.International journal of molecular sciences · 2022Review
- Common Pathogenetic Mechanisms Underlying Aging and Tumor and Means of Interventions.Aging and disease · 2022Article
- STAT3 mediates RCP-induced cancer cell invasion through the NF-κB/Slug/MT1-MMP signaling cascade.Archives of pharmacal research · 2022Article
- Article
- CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein.Molecular cancer · 2022Article
- Plant-Based Antioxidant Extracts and Compounds in the Management of Oral Cancer.Antioxidants (Basel, Switzerland) · 2021Review
- Resveratrol effects in oral cancer cells: a comprehensive review.Medical oncology (Northwood, London, England) · 2021Review
- Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.International journal of molecular sciences · 2021Article
- Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors.Frontiers in oncology · 2021Review
- Rab11-FIP1/RCP Functions as a Major Signalling Hub in the Oncogenic Roles of Mutant p53 in Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Rab coupling protein (RCP) is upregulated in head and neck squamous cell carcinoma (HNSCC) and is correlated with the progression and survival of patients. However, the role of RCP in one of the aggressive types of HNSCC, oral squamous cell carcinoma (OSCC), remains elusive. In the present study, we identified the important role of Zeb1 in RCP-induced OSCC epithelial-to-mesenchymal transition (EMT) and invasion. RCP induces Zeb1 expression, and silencing Zeb1 expression significantly inhibits RCP-induced OSCC invasion. In addition, Zeb1 upregulates MT1-MMP expression to promote OSCC EMT and invasion. Furthermore, we observed that the β1 integrin/EGFR/β-catenin signaling cascade mediates RCP-induced Zeb1 expression to promote OSCC invasion. Notably, we provide evidence that resveratrol (REV) strongly inhibits RCP-induced Zeb1 expression through blocking β1 integrin endosome recycling and EGFR activation, leading to suppression of RCP-induced OSCC invasion, demonstrating the important role of RCP in OSCC invasion and its reversion by REV. Collectively, the present study provides evidence for the first time that RCP aggravates OSCC invasion through increasing Zeb1 expression and subsequently upregulating MT1-MMP expression and that this process is reversed by REV, providing novel biomarkers and indicating the therapeutic potential of REV in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.